Display options
Cite
Nicoletto MO, Tumolo S, Falci C, et al. A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?. Int J Med Sci. 2004;1(2):116-125doi: 10.7150/ijms.1.116.
Nicoletto, M. O., Tumolo, S., Falci, C., Donach, M., Visonà, E., Rosabian, A., Nascimben, O., Cima, G. P., Vinante, O., Azzoni, P., & Fiorentino, M. V. (2004). A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?. International journal of medical sciences, 1(2), 116-125. https://doi.org/10.7150/ijms.1.116
Nicoletto, M O, et al. "A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?." International journal of medical sciences vol. 1,2 (2004): 116-125. doi: https://doi.org/10.7150/ijms.1.116
Nicoletto MO, Tumolo S, Falci C, Donach M, Visonà E, Rosabian A, Nascimben O, Cima GP, Vinante O, Azzoni P, Fiorentino MV. A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?. Int J Med Sci. 2004;1(2):116-125. doi: 10.7150/ijms.1.116. Epub 2004 Jun 01. PMID: 15912203; PMCID: PMC1074719.
Copy Download .nbib Format: NLM
Share it on

Int J Med Sci. 2004;1(2):116-125. doi: 10.7150/ijms.1.116. Epub 2004 Jun 01.

A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?.

International journal of medical sciences

M O Nicoletto, S Tumolo, C Falci, M Donach, E Visonà, A Rosabian, O Nascimben, G P Cima, O Vinante, P Azzoni, M V Fiorentino

Affiliations

  1. GOCCNE Group (Gruppo Oncologico Cooperativo Clinico Nord-Est ovaio), Padua, Italy.

PMID: 15912203 PMCID: PMC1074719 DOI: 10.7150/ijms.1.116

Abstract

Objective. The aim of this study is to verify whether consolidation chemotherapy with Cisplatin improves disease-free survival and/or overall survival in patients affected by epithelial ovarian cancer.Methods. A multicenter study examined 122 randomized patients in complete remission as judged by laparoscopy or laparotomy following first-line chemotherapy consisting of ACy (Adriamycin + Cyclophosphamide), PCy (Cisplatin + Cyclophosphamide), or Mitoxantrone + Carboplatin. Sixty-one of these patients were treated with 3 cycles of 5-Fluorouracil (FU) 500 mg/m2 for 5 days followed by Cisplatin at 100 mg/m2 on the 6th or 7th day every 28 days; the other 61 received no further treatment (nihil group).Results. Sixty patients in the Cisplatin arm were evaluable. There were 36 relapses in the FU+Cisplatin arm and 30 in the nihil arm. Peritoneal relapses were 25% for Cisplatin treatment vs. 16.4 % for nihil. There were 29 deaths in the Cisplatin arm vs. 27 for nihil. Median overall survival time (95 months with Cisplatin vs. 96 months in the nihil group) and median disease-free survival (66 months with Cisplatin vs. 73 in the nihil group) were similar in both arms (p=0.66 and p=0.41, respectively). There were no significant differences in tumor stage and grade between the two arms. Seven patients presented a second neoplasm during follow-up: six in the nihil arm, but only one patient in the Cisplatin arm. Death in these patients was due to the second neoplasm and not to progression of ovarian cancer.Conclusion. Three courses of additional platinum+FU treatment after five cycles of first-line chemotherapy without FU produced no increase in overall survival or disease-free survival.

References

  1. Cancer. 1980 Aug 15;46(4):669-74 - PubMed
  2. Gynecol Oncol. 1989 Oct;35(1):73-4 - PubMed
  3. Semin Oncol. 1984 Sep;11(3):238-50 - PubMed
  4. Gynecol Oncol. 1999 Feb;72(2):215-9 - PubMed
  5. Am J Obstet Gynecol. 1984 Apr 1;148(7):997-1005 - PubMed
  6. Gynecol Oncol. 1991 Aug;42(2):137-41 - PubMed
  7. Cancer. 1988 Jul 1;62(1):40-7 - PubMed
  8. Gynecol Oncol. 1992 Oct;47(1):7-13 - PubMed
  9. J Clin Oncol. 1986 May;4(5):722-9 - PubMed
  10. Obstet Gynecol. 1983 May;61(5):619-23 - PubMed
  11. Gynecol Oncol. 1993 Apr;49(1):30-6 - PubMed
  12. Pathol Oncol Res. 1998;4(2):97-102 - PubMed
  13. Gynecol Oncol. 1989 Feb;32(2):245-7 - PubMed
  14. Gynecol Oncol. 1992 Jun;45(3):284-9 - PubMed
  15. Lancet. 1988 Sep 10;2(8611):599-603 - PubMed
  16. Oncology. 1992;49(6):467-73 - PubMed
  17. J Clin Oncol. 1986 Nov;4(11):1579-85 - PubMed
  18. Semin Oncol. 1975 Sep;2(3):253-66 - PubMed
  19. J Natl Cancer Inst. 2003 Jan 15;95(2):113-25 - PubMed
  20. Int J Gynecol Cancer. 2002 May-Jun;12(3):265-76 - PubMed
  21. Ann Oncol. 1992 Jan;3(1):17-27 - PubMed
  22. Cancer. 1985 May 1;55(9 Suppl):2285-90 - PubMed
  23. Gynecol Oncol. 1998 Apr;69(1):17-22 - PubMed
  24. Ann Oncol. 1997 Apr;8(4):327-33 - PubMed
  25. J Clin Oncol. 1985 Nov;3(11):1455-62 - PubMed
  26. J Clin Oncol. 1988 Mar;6(3):509-16 - PubMed
  27. Eur J Gynaecol Oncol. 1995;16(1):12-7 - PubMed
  28. Cancer. 1989 Apr 15;63(8):1509-13 - PubMed
  29. J Gene Med. 2000 Mar-Apr;2(2):97-106 - PubMed
  30. Anticancer Res. 2000 Mar-Apr;20(2B):1061-7 - PubMed
  31. J Clin Oncol. 1985 Jul;3(7):901-11 - PubMed
  32. Am J Clin Oncol. 1988 Feb;11(1):16-20 - PubMed

Publication Types